Claude Maraoui Sells 49,271 Shares of Journey Medical Co. (NASDAQ:DERM) Stock

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 49,271 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total transaction of $246,847.71. Following the transaction, the chief executive officer now owns 2,003,147 shares of the company’s stock, valued at approximately $10,035,766.47. This represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Claude Maraoui also recently made the following trade(s):

• On Friday, March 7th, Claude Maraoui sold 14,905 shares of Journey Medical stock. The shares were sold at an average price of $5.01, for a total transaction of $74,674.05.
• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11.
• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The shares were sold at an average price of $5.19, for a total transaction of $122,006.52.

Journey Medical Price Performance

Shares of NASDAQ:DERM opened at $5.15 on Wednesday. The company has a 50-day moving average price of $4.62 and a two-hundred day moving average price of $5.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. Journey Medical Co. has a twelve month low of $2.85 and a twelve month high of $6.89. The firm has a market capitalization of $107.58 million, a PE ratio of -5.48 and a beta of 0.97.

Institutional Investors Weigh In On Journey Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nwam LLC purchased a new stake in shares of Journey Medical in the 3rd quarter worth about $59,000. Kovitz Investment Group Partners LLC bought a new position in Journey Medical during the 3rd quarter valued at about $66,000. Cetera Investment Advisers lifted its stake in shares of Journey Medical by 21.8% in the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after purchasing an additional 2,478 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Journey Medical in the 4th quarter worth approximately $80,000. Finally, Citadel Advisors LLC bought a new stake in Journey Medical during the 4th quarter worth approximately $174,000. 7.25% of the stock is currently owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.